marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-05-2024
Vertex Pharmaceuticals Incorporated Balance Sheet 2011-2024 | VRTX
Annual Balance Sheet Vertex Pharmaceuticals Incorporated
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-9.96 B | -10 B | -6.25 B | - | -2.57 B | -2.06 B | -1.06 B | -587 M | -419 M | -330 M | -62.7 M | 742 M | 418 M |
Long Term Debt |
376 M | 431 M | 510 M | - | - | - | - | 297 M | 224 M | 281 M | - | 400 M | 400 M |
Long Term Debt Current |
33.1 M | 48.6 M | 33.3 M | 10.5 M | 11.5 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 898 M | 690 M | 696 M | 766 M | 899 M | 870 M | 565 M | 1.13 B | 846 M |
Total Current Liabilities |
3.55 B | 2.74 B | 2.14 B | 1.88 B | 1.33 B | 1.12 B | 807 M | 793 M | 506 M | 368 M | 398 M | 433 M | 392 M |
Total Liabilities |
5.15 B | 4.24 B | 3.33 B | 3.06 B | 2.23 B | 1.81 B | 1.5 B | 1.56 B | 1.41 B | 1.24 B | 963 M | 1.56 B | 1.24 B |
Deferred Revenue |
- | - | - | - | - | - | 238 M | 79.4 M | 16.3 M | 17.5 M | 21.5 M | 27.6 M | 45 M |
Retained Earnings |
10.1 B | 6.52 B | 3.2 B | 859 M | -1.85 B | -2.99 B | -5.12 B | -5.37 B | -5.26 B | -4.71 B | -3.97 B | -3.52 B | -3.41 B |
Total Assets |
22.7 B | 18.2 B | 13.4 B | 11.8 B | 8.32 B | 6.25 B | 3.55 B | 2.9 B | 2.5 B | 2.33 B | 2.32 B | 2.76 B | 2.2 B |
Cash and Cash Equivalents |
10.4 B | 10.5 B | 6.8 B | 5.99 B | 3.11 B | 2.65 B | 1.67 B | 1.18 B | 715 M | 625 M | 569 M | 489 M | 475 M |
Book Value |
17.6 B | 13.9 B | 10.1 B | 8.69 B | 6.09 B | 4.44 B | 2.04 B | 1.34 B | 1.09 B | 1.1 B | 1.36 B | 1.2 B | 966 M |
Total Shareholders Equity |
17.6 B | 13.9 B | 10.1 B | 8.69 B | 6.09 B | 4.44 B | 2.03 B | 1.16 B | 940 M | 1.08 B | 1.36 B | 999 M | 787 M |
All numbers in USD currency
Quarterly Balance Sheet Vertex Pharmaceuticals Incorporated
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
114 M | 347 M | 362 M | 376 M | 390 M | 404 M | 418 M | 431 M | 442 M | - | 496 M | 510 M | 513 M | 525 M | 530 M | 539 M | 539 M | 539 M | 539 M | 539 M | 539 M | 539 M | 539 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 105 M | 105 M | 105 M |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
6.61 B | 5.36 B | 5.37 B | 5.15 B | 5.21 B | 4.88 B | 4.54 B | 4.24 B | 3.68 B | - | 3.35 B | 3.33 B | 3.09 B | 3.03 B | 3.13 B | 3.06 B | 3.06 B | 3.06 B | 3.06 B | 2.23 B | 2.23 B | 2.23 B | 2.23 B | 1.81 B | 1.81 B | 1.81 B | 1.81 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.56 B | 1.56 B | 1.56 B | 1.56 B | 1.4 B | 1.4 B | 1.4 B | 1.4 B | 1.24 B | 1.24 B | 1.24 B | 1.24 B | 963 M | 963 M | 963 M | 963 M | 1.52 B | 1.52 B | 1.52 B | 1.52 B | 1.24 B | 1.24 B | 1.24 B | 1.24 B |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.17 M | 13 M | 7.28 M | 6.06 M | 6 M | 6 M | 6 M | 6 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 21.5 M | 21.5 M | 21.5 M | 21.5 M | 27.6 M | 27.6 M | 27.6 M | 27.6 M | 45 M | 45 M | 45 M | 45 M |
Retained Earnings |
8.69 B | 7.65 B | 11.2 B | 10.1 B | 9.17 B | 8.14 B | 7.22 B | 6.52 B | 5.7 B | - | 3.96 B | 3.2 B | 2.43 B | 1.58 B | 1.51 B | 859 M | 859 M | 859 M | 859 M | -1.85 B | -1.85 B | -1.85 B | -1.85 B | -2.99 B | -2.99 B | -2.99 B | -2.99 B | -5.12 B | -5.12 B | -5.12 B | -5.12 B | -5.37 B | -5.37 B | -5.37 B | -5.37 B | -5.26 B | -5.26 B | -5.26 B | -5.26 B | -4.71 B | -4.71 B | -4.71 B | -4.71 B | -3.97 B | -3.97 B | -3.97 B | -3.97 B | -3.52 B | -3.52 B | -3.52 B | -3.52 B | -3.41 B | -3.41 B | -3.41 B | -3.41 B |
Total Assets |
22.2 B | 20.1 B | 23.9 B | 22.7 B | 21.7 B | 20.3 B | 19 B | 18.2 B | 16.7 B | - | 14.3 B | 13.4 B | 12.6 B | 12.2 B | 12.1 B | 11.8 B | 11.8 B | 11.8 B | 11.8 B | 8.32 B | 8.32 B | 8.32 B | 8.32 B | 6.25 B | 6.25 B | 6.25 B | 6.25 B | 3.55 B | 3.55 B | 3.55 B | 3.55 B | 2.9 B | 2.9 B | 2.9 B | 2.9 B | 2.5 B | 2.5 B | 2.5 B | 2.5 B | 2.33 B | 2.33 B | 2.33 B | 2.33 B | 2.32 B | 2.32 B | 2.32 B | 2.32 B | 2.76 B | 2.76 B | 2.76 B | 2.76 B | 2.2 B | 2.2 B | 2.2 B | 2.2 B |
Cash and Cash Equivalents |
5.24 B | 4.58 B | 9.16 B | 10.4 B | 11.1 B | 10.2 B | 9.29 B | 10.5 B | 9.17 B | 8.7 B | 7.6 B | 6.8 B | 6.28 B | 6.06 B | 6.3 B | 5.99 B | 5.99 B | 5.99 B | 5.99 B | 3.11 B | 3.11 B | 3.11 B | 3.11 B | 2.65 B | 2.65 B | 2.65 B | 2.65 B | 1.67 B | 1.67 B | 1.67 B | 1.67 B | 1.18 B | 1.18 B | 1.18 B | 1.18 B | 715 M | 715 M | 715 M | 715 M | 625 M | 625 M | 625 M | 625 M | 569 M | 569 M | 569 M | 569 M | 489 M | 489 M | 489 M | 489 M | 475 M | 475 M | 475 M | 475 M |
Book Value |
15.6 B | 14.8 B | 18.5 B | 17.6 B | 16.5 B | 15.5 B | 14.4 B | 13.9 B | 13 B | - | 10.9 B | 10.1 B | 9.53 B | 9.2 B | 8.98 B | 8.69 B | 8.69 B | 8.69 B | 8.69 B | 6.09 B | 6.09 B | 6.09 B | 6.09 B | 4.44 B | 4.44 B | 4.44 B | 4.44 B | 2.04 B | 2.04 B | 2.04 B | 2.04 B | 1.34 B | 1.34 B | 1.34 B | 1.34 B | 1.09 B | 1.09 B | 1.09 B | 1.09 B | 1.1 B | 1.1 B | 1.1 B | 1.1 B | 1.36 B | 1.36 B | 1.36 B | 1.36 B | 1.23 B | 1.23 B | 1.23 B | 1.23 B | 966 M | 966 M | 966 M | 966 M |
Total Shareholders Equity |
15.6 B | 14.8 B | 18.5 B | 17.6 B | 16.5 B | 15.5 B | 14.4 B | 13.9 B | 13 B | 11.9 B | 10.9 B | 10.1 B | 9.53 B | 9.2 B | 8.98 B | 8.69 B | 8.69 B | 8.69 B | 8.69 B | 6.09 B | 6.09 B | 5.07 B | 6.09 B | 4.44 B | 2.91 B | 2.69 B | 2.4 B | 2.03 B | 2.03 B | 2.03 B | 2.03 B | 1.16 B | 1.16 B | 1.16 B | 1.16 B | 940 M | 940 M | 940 M | 940 M | 1.08 B | 1.08 B | 1.08 B | 1.08 B | 1.36 B | 1.36 B | 1.36 B | 1.36 B | 999 M | 999 M | 999 M | 999 M | 787 M | 787 M | 787 M | 787 M |
All numbers in USD currency